Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
BMC Cancer, 09/24/09

Partheen K et al. – The loss of ITGB3 expression in tumours from deceased patients and high expression in tumours from survivors could be used as a biomarker for patients with advanced serous tumours.

Methods

Analysed the gene expressions of CLU, ITGB3, CAPG, and PRAME
30 advanced staged serous adenocarcinomas with quantitative real-time polymerase chain reaction (QPCR) and the protein levels were analysed in 98 serous adenocarcinomas with western blot for semiquantitative analysis
Statistical difference in mRNA and protein expressions between tumours from survivors and tumours from deceased patients was evaluated using the Mann-Whitney U test

Results

Gene and protein ITGB3 were significantly more expressed in tumours from survivors compared to tumours from deceased patients
No significant differences were detected for the other three genes or proteins CLU, CAPG, and PRAME

<< Previous
Health states of women after conservative surgery and radiation...

Next >>
Comparative evaluation of cell-free tumor DNA in blood and...